论文部分内容阅读
目的探讨每周多西他赛联合顺铂治疗非小细胞肺癌(NSCLC)的临床疗效。方法多西他赛总量60mg/m2,第1、8d静脉滴入持续2h;为预防过敏反应和体液潴留,患者用多西他赛前1日开始口服地塞米松7.5mg/次,2次/d连服3d。顺铂75mg/m2,静脉滴入,分5～6d平均给药。21d为1个周期,每个周期后对不良反应进行评估,至少2个周期后判定疗效。结果本组CR2例,PR25例,SD15例,PD16例,总有效率46.6%。患者毒副反应较轻,以骨髓抑制及消化道反应为主。其中白细胞减少发生率为75.9%(44/58),Ⅲ到Ⅳ度仅占5.2%(3/58),恶心、呕吐发生率为43.1%(25/58),未出现Ⅳ度。未出现严重的肝肾功能损害、水钠潴留、过敏反应和心脏损害,无化疗相关死亡病例。结论每周多西他赛联合顺铂的化疗方案具有更轻的毒副反应和更好的患者耐受性,疗效确切,有利于提高患者的生存质量,是目前非小细胞肺癌较理想的化疗方案。
Objective To investigate the clinical efficacy of weekly docetaxel plus cisplatin in the treatment of non-small cell lung cancer (NSCLC). Methods Docetaxel 60mg / m2, 1,8d intravenous infusion for 2h; in order to prevent allergic reactions and fluid retention, patients taking docetaxel on the 1st day before starting oral dexamethasone 7.5mg / time, twice / d even service 3d. Cisplatin 75mg / m2, intravenous infusion, sub-5 ~ 6d averaged. 21d for a cycle, after each cycle of adverse reactions were evaluated, at least 2 cycles to determine the efficacy. Results The group of CR2 cases, PR25 cases, SD15 cases, PD16 cases, the total efficiency of 46.6%. Patients with mild side effects, with bone marrow suppression and gastrointestinal reactions based. Incidence of leukopenia was 75.9% (44/58), grade III to grade Ⅳ accounted for only 5.2% (3/58), nausea and vomiting was 43.1% (25/58), and no grade IV was found. No serious liver and kidney dysfunction, Shuinazhuliu, allergic reactions and heart damage, no chemotherapy-related deaths. Conclusion weekly docetaxel combined with cisplatin chemotherapy has lighter toxicity and better patient tolerance, curative effect is exact, is conducive to improving the quality of life of patients, is the ideal chemotherapy for non-small cell lung cancer Program.